MX338134B - Formas salinas de adicion de acido de conjugados de polimeros-farmaco y metodos de alcoxilacion. - Google Patents

Formas salinas de adicion de acido de conjugados de polimeros-farmaco y metodos de alcoxilacion.

Info

Publication number
MX338134B
MX338134B MX2012005794A MX2012005794A MX338134B MX 338134 B MX338134 B MX 338134B MX 2012005794 A MX2012005794 A MX 2012005794A MX 2012005794 A MX2012005794 A MX 2012005794A MX 338134 B MX338134 B MX 338134B
Authority
MX
Mexico
Prior art keywords
acid salt
polymer
mixed
salt forms
drug conjugate
Prior art date
Application number
MX2012005794A
Other languages
English (en)
Other versions
MX2012005794A (es
Inventor
Brian Bray
Antoni Kozlowski
Anthony O Chong
Seoju Lee
Bhalchandra V Joshi
Shaoyong Nie
Patrick Spence
Sachin Tipnis
Greg Lavaty
David Swallow
Samuel Macmanus
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2012005794A publication Critical patent/MX2012005794A/es
Publication of MX338134B publication Critical patent/MX338134B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Support Of Aerials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una sal ácida mezclada de un conjugado de fármaco de polímero hidrosoluble, junto con los métodos mencionados para elaborar y utilizar el mismo; la sal ácida mezclada se forma establemente y parece ser más resistente a la degradación hidrolítica que la sal ácida pura predominantemente correspondiente o las formas de base libre del conjugado de fármaco de polímero; la sal ácida mezclada se prepara y recupera de manera reproducible y proporciona ventajas sorprendentes sobre la forma de sal ácida no mezclada del conjugado de fármaco de polímerohidrosoluble.
MX2012005794A 2009-11-18 2010-11-18 Formas salinas de adicion de acido de conjugados de polimeros-farmaco y metodos de alcoxilacion. MX338134B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26246309P 2009-11-18 2009-11-18
US29007209P 2009-12-24 2009-12-24
PCT/US2010/057289 WO2011063156A2 (en) 2009-11-18 2010-11-18 Acid salt forms of polymer-drug conjugates and alkoxylation methods

Publications (2)

Publication Number Publication Date
MX2012005794A MX2012005794A (es) 2012-10-09
MX338134B true MX338134B (es) 2016-04-01

Family

ID=43639124

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012005795A MX337393B (es) 2009-11-18 2010-11-18 Forma salina de un conjugado de polímero-farmaco con multiples brazos.
MX2012005794A MX338134B (es) 2009-11-18 2010-11-18 Formas salinas de adicion de acido de conjugados de polimeros-farmaco y metodos de alcoxilacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012005795A MX337393B (es) 2009-11-18 2010-11-18 Forma salina de un conjugado de polímero-farmaco con multiples brazos.

Country Status (24)

Country Link
US (5) US9226969B2 (es)
EP (3) EP3498754A1 (es)
JP (3) JP5951496B2 (es)
KR (2) KR101790804B1 (es)
CN (2) CN102711837B (es)
AU (1) AU2010321882B2 (es)
BR (2) BR112012011947B8 (es)
CA (3) CA2780645C (es)
CY (1) CY1121700T1 (es)
DK (1) DK2501413T3 (es)
EA (2) EA023503B1 (es)
ES (2) ES2623677T3 (es)
HR (1) HRP20191138T1 (es)
HU (1) HUE043689T2 (es)
IL (2) IL219866A (es)
LT (1) LT2501413T (es)
ME (1) ME03396B (es)
MX (2) MX337393B (es)
PL (1) PL2501413T3 (es)
PT (1) PT2501413T (es)
RS (1) RS58901B1 (es)
SI (1) SI2501413T1 (es)
SM (1) SMT201900294T1 (es)
WO (2) WO2011063158A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
CA2780645C (en) 2009-11-18 2018-01-16 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
JP6138140B2 (ja) * 2011-10-25 2017-05-31 ネクター セラピューティクス 癌患者の治療
WO2013162387A1 (en) * 2012-04-26 2013-10-31 Amylex Pharmaceuticals, Inc Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof
JP6300460B2 (ja) * 2012-07-20 2018-03-28 キヤノン株式会社 化合物、および前記化合物を有する光音響イメージング用造影剤
WO2014036566A1 (en) * 2012-08-31 2014-03-06 Virginia Commonwealth University Clickable polyoxetane carrier for drug delivery
CN104813167B (zh) 2012-11-28 2019-04-09 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
US9493766B2 (en) * 2013-02-04 2016-11-15 Corning Incorporated PCR reaction cleanup buffers
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
WO2014194289A1 (en) 2013-05-31 2014-12-04 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
CN104225611B (zh) * 2013-06-18 2017-06-30 天津键凯科技有限公司 达沙替尼与非线性构型聚乙二醇的结合物
CA3191031A1 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
CN106061483B (zh) * 2013-10-04 2021-01-08 普洛林克斯有限责任公司 Sn-38的缓释结合物
JP5721806B2 (ja) * 2013-10-04 2015-05-20 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 副作用のない抗癌剤
AU2015206667B2 (en) 2014-01-14 2020-05-14 Nektar Therapeutics Combination-based treatment method
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3228650B1 (en) * 2014-12-04 2022-03-09 Delta-Fly Pharma, Inc. Novel peg derivative
EP3253777B9 (en) * 2015-02-04 2021-11-17 United Arab Emirates University Rvg derived peptides
AU2016305087B2 (en) 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
CN107019803B (zh) * 2016-01-29 2020-09-15 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
CN107469089B (zh) * 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
AU2018207283C1 (en) 2017-01-10 2024-05-02 Nektar Therapeutics Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
WO2018143122A1 (ja) * 2017-02-02 2018-08-09 アルプス電気株式会社 平衡式電流センサ
KR102279429B1 (ko) 2017-04-21 2021-07-20 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. 멀티 암 표적 항암 콘쥬게이트
CN108727584B (zh) * 2017-04-21 2021-01-05 博瑞生物医药（苏州）股份有限公司 抗癌偶联物
WO2019046452A1 (en) * 2017-09-01 2019-03-07 Arizona Board Of Regents On Behalf Of Arizona State University THIXOTROPIC BIOCOMPATIBLE GEL FOR OBSERVATION OF LIVING CELLS IN COMPUTER-ASSISTED TOMOGRAPHY ON CELLS
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
WO2019096096A1 (zh) * 2017-11-14 2019-05-23 博瑞生物医药（苏州）股份有限公司 多臂靶向偶联物
CN107854693B (zh) * 2017-11-14 2020-07-14 高瑞耀业(北京)科技有限公司 整合素受体靶向的抗癌偶联物
CN109776787B (zh) * 2017-11-14 2021-08-03 博瑞生物医药（苏州）股份有限公司 多臂靶向偶联物
CN111526891B (zh) * 2017-12-27 2023-10-20 三洋化成工业株式会社 药品原料药用原料或药品用添加物和使用了它们的药品原料药或药品
JP2021510702A (ja) 2018-01-12 2021-04-30 プロリンクス エルエルシー 相乗的がん治療
CN112367985A (zh) 2018-01-31 2021-02-12 明尼苏达大学董事会 用于治疗肺水肿或肺炎的组合物和方法
CN110256533B (zh) * 2018-03-12 2022-05-10 博瑞生物医药（苏州）股份有限公司 一种高纯度的多臂抗癌偶联物的提取方法
CN110577552A (zh) * 2018-06-08 2019-12-17 遵义医学院 喜树碱-甘氨酸-5,6-双脱氢去甲斑蝥素结合物及其应用
EP3852793B1 (en) 2018-09-17 2025-11-19 The Children's Hospital Of Philadelphia Macromolecular prodrug peg-[sn22]4
CN111603567B (zh) 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
US20220305025A1 (en) * 2019-08-15 2022-09-29 The Research Foundation For The State University Of New York Phosphatidylserine binding molecules block immune suppression of tumor associated exosomes
MX2022011821A (es) 2020-03-27 2022-10-10 Univ Minnesota Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
CN114705801B (zh) * 2022-01-24 2024-02-27 中国食品药品检定研究院(国家药品监督管理局医疗器械标准管理中心、中国药品检验总所) 一种利福霉素类药物中亚硝酸根离子的测定方法
WO2025053315A1 (ko) * 2023-09-08 2025-03-13 파로스젠 주식회사 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1222261B (de) * 1963-04-20 1966-08-04 Bayer Ag Verfahren zur Herstellung von Polyaethern durch Polymerisation von Alkylenoxyden
GB1157753A (en) * 1966-06-24 1969-07-09 Bp Chem Int Ltd Improvements in or relating to Synthetic Lubricants
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5399728A (en) * 1993-04-05 1995-03-21 Arco Chemical Technology, L.P. Process for the preparation of highly esterified alkoxylated polyol compositions
GB9704126D0 (en) * 1997-02-27 1997-04-16 Ici Plc Surfactants
DE19817676A1 (de) * 1998-04-21 1999-10-28 Bayer Ag Verfahren zur aufarbeitungsfreien Herstellung langkettiger Polyetherpolyole
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
DE19937114C2 (de) * 1999-08-06 2003-06-18 Bayer Ag Verfahren zur Herstellung von Polyetherpolyolen
US6762325B2 (en) * 2001-05-16 2004-07-13 Nippon Shokubai Co., Ltd. Method for production of alkoxylated compound
SE523934C2 (sv) * 2001-09-24 2004-06-01 Perstorp Specialty Chem Ab Förfarande för av alkoxylering av di-, tri och polyalkoholer
US6608076B1 (en) * 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
BR0315198A (pt) * 2002-10-09 2005-08-30 Insert Therapeutics Inc Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos
US20050043215A1 (en) * 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
PT2644206T (pt) * 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
CN1852740B (zh) * 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1725262B1 (en) * 2004-03-15 2021-05-26 Nektar Therapeutics Polymer-based compositions and conjugates of hiv entry inhibitors
US7897772B2 (en) * 2004-10-01 2011-03-01 Kabushiki Kaisha Yakult Honsha Acid addition salt of irinotecan
US8273339B2 (en) 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
EP1926768B1 (en) * 2005-07-18 2011-09-14 Nektar Therapeutics Branched functionalized polymers using branched polyol cores
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
IE20060565A1 (en) * 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
JP5105166B2 (ja) * 2007-12-19 2012-12-19 公益財団法人野口研究所 ポリエーテルの製造方法
CA2780645C (en) 2009-11-18 2018-01-16 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate

Also Published As

Publication number Publication date
EA023503B1 (ru) 2016-06-30
CA2780779C (en) 2020-02-04
LT2501413T (lt) 2019-05-10
IL219866A (en) 2017-03-30
EA201290342A1 (ru) 2012-10-30
US20130231359A1 (en) 2013-09-05
US9226969B2 (en) 2016-01-05
JP5951496B2 (ja) 2016-07-13
CA2780645C (en) 2018-01-16
PL2501413T3 (pl) 2019-09-30
BR112012011947B1 (pt) 2021-05-18
HUE043689T2 (hu) 2019-09-30
HRP20191138T1 (hr) 2019-09-20
PT2501413T (pt) 2019-07-10
CN102711836A (zh) 2012-10-03
EP2501412A1 (en) 2012-09-26
CA3063465C (en) 2023-01-03
JP5901073B2 (ja) 2016-04-06
KR20120101070A (ko) 2012-09-12
KR20120104243A (ko) 2012-09-20
CN102711836B (zh) 2017-05-10
EA201200751A8 (ru) 2014-07-30
WO2011063158A1 (en) 2011-05-26
MX2012005794A (es) 2012-10-09
EP2501413B1 (en) 2019-03-27
IL219866A0 (en) 2012-07-31
DK2501413T3 (da) 2019-06-11
MX337393B (es) 2016-03-02
ES2723026T3 (es) 2019-08-21
US11834553B2 (en) 2023-12-05
EA024533B1 (ru) 2016-09-30
CA2780779A1 (en) 2011-05-26
WO2011063156A2 (en) 2011-05-26
CA2780645A1 (en) 2011-05-26
WO2011063156A3 (en) 2011-08-25
JP2016006127A (ja) 2016-01-14
SMT201900294T1 (it) 2019-07-11
MX2012005795A (es) 2012-09-07
IL219865A (en) 2017-03-30
RS58901B1 (sr) 2019-08-30
CA3063465A1 (en) 2011-05-26
KR101779229B1 (ko) 2017-09-18
EP3498754A1 (en) 2019-06-19
BR112012011947B8 (pt) 2021-05-25
EA201200751A1 (ru) 2013-03-29
AU2010321880A1 (en) 2012-06-07
IL219865A0 (en) 2012-07-31
US20150105519A1 (en) 2015-04-16
CN102711837B (zh) 2016-10-19
US20210024693A1 (en) 2021-01-28
ME03396B (me) 2020-01-20
CN102711837A (zh) 2012-10-03
KR101790804B1 (ko) 2017-10-26
JP2013511540A (ja) 2013-04-04
SI2501413T1 (sl) 2019-06-28
BR112012011943A2 (pt) 2018-09-11
EP2501413A2 (en) 2012-09-26
US20160200867A1 (en) 2016-07-14
EP2501412B1 (en) 2017-03-29
EA201290342A8 (ru) 2014-07-30
AU2010321882B2 (en) 2016-01-14
AU2010321882A1 (en) 2012-05-31
JP2013511539A (ja) 2013-04-04
BR112012011947A2 (pt) 2018-09-11
US9320808B2 (en) 2016-04-26
ES2623677T3 (es) 2017-07-12
CY1121700T1 (el) 2020-07-31
US20130143909A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
WO2011063156A3 (en) Acid salt forms of polymer-drug conjugates and alkoxylation methods
IL210646A0 (en) Hiv vaccine based on targeting maximized gag and nef to dendritic cells
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
WO2009140423A3 (en) Targeted polymer bioconjugates
WO2011059326A3 (en) Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers
EA201070657A1 (ru) Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
WO2011062965A8 (en) Targeting monomers and polymers having targeting blocks
MX2018013332A (es) Conjugados de pirrolobenzodiazepina diana.
MX2013014583A (es) Conjugados de proteina-polimero-farmaco.
MY156872A (en) Biodegradable polyethylene glycol based water-insoluble hydrogels
MX343337B (es) Metodos de preparacion de conjugados.
AU327564S (en) Handset
MY157838A (en) Metalworking fluid
AU327541S (en) Handset
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
WO2013020079A3 (en) Conjugates of an il-11 moiety and a polymer
AU327562S (en) Handset
WO2008156012A1 (ja) モータリン siRNAを含む癌治療剤
EP3257525A3 (en) Vaccine compositions
WO2010024557A3 (en) Biopolymer conjugates comprising an interleukin-11 analog
MY156568A (en) Peptide-polymer conjugates
HK1155065A (en) Hiv vaccine based on targeting maximized gag and nef to dendritic cells
TW201120104A (en) Chitosan-conductive polymer hybrid polymer composition with antioxidant properties
AU327059S (en) A digging point
AU327061S (en) A digging point

Legal Events

Date Code Title Description
FG Grant or registration